Asset Details
Do you wish to reserve the book?
Personalized nanovaccines for treating solid cancer metastases
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Personalized nanovaccines for treating solid cancer metastases
Do you wish to request the book?
Personalized nanovaccines for treating solid cancer metastases
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Personalized nanovaccines for treating solid cancer metastases
2024
Overview
Cancer vaccines have garnered attention as a potential treatment for cancer metastases. Nevertheless, the clinical response rate to vaccines remains < 30%. Nanoparticles stabilize vaccines and improve antigen recognition and presentation, resulting in high tumor penetration or accumulation, effective co-distribution of drugs to the secondary lymphatic system, and adaptable antigen or adjuvant administration. Such vaccine-like nanomedicines have the ability to eradicate the primary tumors as well as to prevent or eliminate metastases. This review examines state-of-the-art nanocarriers developed to deliver tumor vaccines to metastases, including synthetic, semi-biogenic, and biogenic nanosystems. Moreover, it highlights the physical and pharmacological properties that enhance their anti-metastasis efficiency. This review also addresses the combination of nanovaccines with cancer immunotherapy to target various steps in the metastatic cascade, drawing insights from preclinical and clinical studies. The review concludes with a critical analysis of the challenges and frameworks linked to the clinical translation of cancer nanovaccines.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Analysis
/ Animals
/ Antigens
/ B cells
/ Cancer
/ Cancer Vaccines - administration & dosage
/ Cancer Vaccines - therapeutic use
/ Humans
/ Hypoxia
/ Medicine
/ molecular engineering for drug discovery
/ Nanoparticles - therapeutic use
/ New developments in delivery technology
/ Oncology
/ Patients
/ Precision Medicine - methods
/ Review
/ Tumor
/ Tumors
/ Vaccines
